Ovarian cancer

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Retrieved on: 
Wednesday, April 17, 2024
ATM, Therapy, Ovarian cancer, Pharmaceutical industry

Boston (April 17, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it had been granted an extension until May 14, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(1).

Key Points: 
  • Boston (April 17, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it had been granted an extension until May 14, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(1).
  • On February 1, 2024, Allarity Therapeutics presented a strategic plan to the Nasdaq Hearings Panel, detailing both immediate and long-term strategies aimed at regaining compliance with the requirements outlined in Nasdaq Listing Rules 5550(a)(2) and 5550(b).
  • Following a recent presentation on the progress of the plan's execution to date, Nasdaq issued an extension, granting Allarity additional time until May 14, 2024, to demonstrate full compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000.
  • The steps that Allarity has taken to regain compliance with Nasdaq’s listing requirements include that the Company recently implemented a 1-for-20 reverse stock split effective April 9, 2024, aimed at regaining bid price compliance, rule 5550(a)(2).

Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics

Retrieved on: 
Wednesday, April 17, 2024
University, Woman, Therapy, Patient, Merck Group, Clinical trial, Biotechnology, Ovarian cancer, Medical imaging

Sound Bioventures participated in the financing round, which raised a total of £19M ($24.5M), and joins a strong existing investor syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford.

Key Points: 
  • Sound Bioventures participated in the financing round, which raised a total of £19M ($24.5M), and joins a strong existing investor syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford.
  • In conjunction with this financing, Thomas Tan, Principal at Sound Bioventures, will join Theolytics’ Board of Directors.
  • Proceeds from the new financing will further strengthen Theolytics’ position as it advances its lead oncolytic adenovirus - THEO-260 - into clinical trials in ovarian cancer.
  • Thomas Tan, Principal at Sound Bioventures, said; “The oncolytic virus modality is rapidly evolving, and we believe that Theolytics is well positioned at the forefront of this exciting therapy area.

Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor

Retrieved on: 
Wednesday, April 17, 2024
University, Merck Group, Clinical trial, Patient, Biotechnology, Woman, Ovarian cancer, Medical imaging

Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today announced it has successfully closed its latest financing round, raising a total of £19M ($24.5M) with the addition of Sound Bioventures as a new investor.

Key Points: 
  • Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today announced it has successfully closed its latest financing round, raising a total of £19M ($24.5M) with the addition of Sound Bioventures as a new investor.
  • Sound Bioventures joins a strong international syndicate of existing investors participating in the round that includes M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford.
  • The proceeds from this financing round further strengthen the company’s position as it advances its lead oncolytic adenovirus - THEO-260 - into clinical trials in ovarian cancer.
  • Following this investment, Thomas Tan, Principal at Sound Bioventures, will join Theolytics’ Board of Directors.

Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization

Retrieved on: 
Wednesday, May 1, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Mesothelioma, Imerys, Safety, State, JNJ, Bankruptcy, Johnson & Johnson, MDL, Science, Worldwide, Cyprus Mines Corporation, Talc, LLT, Ovarian cancer, Insurance

“The Plan is the culmination of our consensual resolution strategy that we announced last October,” said Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson.

Key Points: 
  • “The Plan is the culmination of our consensual resolution strategy that we announced last October,” said Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson.
  • The remaining pending personal injury lawsuits relate to mesothelioma and will be addressed outside of the Plan.
  • The State consumer protection claims will also be addressed outside the Plan; the Company already has agreements in principle to do so.
  • In light of those risks, counsel representing the overwhelming majority of current ovarian claimants assisted in the development and support the Plan.

Beasley Allen Law Firm: Attorneys for Women Harmed by Johnson & Johnson’s Talcum Powder Resist Company’s Attempt to Stuff Ballot Box in Unprecedented Third Attempted Bankruptcy

Retrieved on: 
Wednesday, May 1, 2024
Legal, Professional Services, J&J, Asbestos, Mesothelioma, Cancer, Woman, Bankruptcy, Bankruptcy Code, MDL, Ashcraft, Medicine, Action Replay, Talc, Lawyer, Ovarian cancer, Insurance

Now the company promises minimal payments for these “worthless” claims in exchange for a “yes” vote.

Key Points: 
  • Now the company promises minimal payments for these “worthless” claims in exchange for a “yes” vote.
  • Medical costs for treating ovarian cancer can total more than $1.5 million per patient, with an average near $220,000.
  • In October 2021, at the time of the first J&J/LTL bankruptcy, there were approximately 35,000 lawsuits alleging talc-caused ovarian cancer or mesothelioma.
  • “This will be the third bankruptcy in three years,” noted trial lawyer Richard Golomb , of Golomb Legal P.C.

Arsenal Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of AB-2100 in Development as a Treatment for Clear-cell Renal Cell Carcinoma

Retrieved on: 
Tuesday, April 30, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, PSMA, Integrated circuit, FDA, CA9, Protein, CRISPR, SPA, Safety, ICT, Malignancy, Tumor microenvironment, Engineering, DNA, Patient, Electroporation, Neoplasm, Toxicity, Antigen, Renal cell carcinoma, VEGF, Ovarian cancer, Transgene, TME

Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that the first patient has been dosed with AB-2100 in a multi-center, open-label Phase 1/2 clinical trial for patients with clear-cell renal cell carcinoma (ccRCC).

Key Points: 
  • Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that the first patient has been dosed with AB-2100 in a multi-center, open-label Phase 1/2 clinical trial for patients with clear-cell renal cell carcinoma (ccRCC).
  • These engineering features will potentially enable the patient’s immune system to destroy ccRCC cells without harming normal tissues.
  • “Kidney cancer is an immunologically responsive malignancy with several FDA approved immunotherapies on the market.
  • A multi-center, open-label phase 1 dose escalation trial ( NCT05617755 ) of AB-1015, under investigation for the treatment of ovarian cancer, is currently enrolling.

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Retrieved on: 
Thursday, April 11, 2024
Disease, AIM, News, Ovarian cancer

OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website.

Key Points: 
  • OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website.
  • For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, discussed the Company’s recent news release regarding top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have a powerful synergistic effect that could be far more effective than pembrolizumab alone as a therapy for the disease.

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Retrieved on: 
Wednesday, April 10, 2024
IC50, AP3, Drug resistance, Proteomics, PDX, CDX, Cell cycle, PKMYT1, Patient, Medicine, WEE1, Neoplasm, ACRV, AACR, Drug development, Biomarker, Drug discovery, Therapy, Ovarian cancer, Pharmaceutical industry

WATERTOWN, Mass., April 10, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced data from two posters that the company presented at the American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • “Uniquely enabled by AP3, we designed a selective and potent dual inhibitor of both WEE1 and PKMYT1, ACR-2316, designed for potent single agent activity.
  • We presented preclinical data showing its superior activity versus benchmark WEE1 and PKMYT1 single-agent inhibitors in multiple cancer models and look forward to advancing this compound into the clinic.
  • The complete responses observed with ACR-2316 in human tumor xenograft mouse models were associated with strong WEE1 and balanced PKMYT1 inhibition activity in tumors.
  • This corresponded with the subsequent upregulation of ACR-368 OncoSignature biomarkers, indicating that the OncoSignature assay can predict which ULDG sensitized tumors would be responsive to treatment with ACR-368.

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, April 10, 2024
PFS, University, Epithelium, UPMC Magee-Womens Hospital, Pancreatic cancer, Triple-negative breast cancer, Colorectal cancer, Research, Cisplatin, AIM, MD, Peritoneum, Gynecologic Oncology (journal), UPMC, Gynaecology, Disease, Liver, Patient, CXCL10, CXCL11, Reproductive Sciences, Progression-free survival, Data analysis, Neoplasm, Biomarker, CXCL9, Cancer, RNA, Ovarian cancer, Medical imaging

See further details on the study “Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer” at ClinicalTrials.gov: NCT03734692 .

Key Points: 
  • See further details on the study “Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer” at ClinicalTrials.gov: NCT03734692 .
  • Additionally, the immunological signature supporting this synergistic enhancement has been seen in other clinical trials, including with pancreatic cancer ( 1 , 2 ) metastatic triple-negative breast cancer and colorectal cancer metastatic to the liver .
  • Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on several immune cells, epithelial cells and most solid tumors.
  • Additionally, Keynote-100’s median PFS was 2.1 months, or significantly less than that seen in the ongoing Ampligen study.

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024

Retrieved on: 
Wednesday, April 10, 2024
Cancer, Interleukin, Pembrolizumab, Merck & Co., Pancreatic serous cystadenoma, Tumor microenvironment, Immunoglobulin E, Patient, TILT, B cell, Potyvirus, Immunomodulation, AACR, Neoplasm, Merck, Ovarian cancer, Injection, Platinum, Pharmaceutical industry

HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • Analysis of biological samples revealed insights into mechanism of action, including an immunological profile potentially predictive of clinical response.
  • The results presented at AACR 2024, along with data from other ongoing trials, underscore the promise of TILT-123 as a novel cancer therapy.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.